• About us
• Contact

Advertisement

Product › Details

AI-based drug discovery software

	Next higher product group	drug discovery software

Record changed: 2023-04-18

Advertisement

More documents for AI-based drug discovery software

• [1] Merck KGaA. (12/5/23). "Press Release: Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis". Darmstadt....
• [2] Genentech, Inc.. (11/21/23). "Press Release: Genentech and Nvidia Enter Into Strategic AI Research Collaboration to Accelerate Drug Discovery and Development". South San Francisco, CA....
• [3] CellPhenomics GmbH. (9/29/23). "Press Release: Kyan Technologies, Alentis Therapeutics, and CellPhenomics Join Forces Combining Cutting-edge Optim.AI and PD3D Models to Advance Claudin-1 Expression Research". Singapore, Berlin & Allschwil....
• [4] Novo Nordisk A/S. (9/25/23). "Press Release: Valo Health and Novo Nordisk to Collaborate to Discover and Develop Novel Treatments for Cardiometabolic Diseases Using Human Data and Artificial Intelligence". Bagsværd & Boston, MA....
• [5] SandboxAQ. (6/22/23). "Press Release: SandboxAQ Announces Biopharma Molecular Simulation Division to Speed Life-Saving Drugs to Patients Through AI and Quantum Solutions". Palo Alto, CA....
• [6] CellPhenomics GmbH. (4/14/23). "Press Release: CELLphenomics’ and Kyan Therapeutics Combined Platforms Provide Best-in-Class Solutions to Support the Biopharma Industry". Berlin & Singapore....
• [7] BioNTech SE. (1/10/23). "Press Release: BioNTech to Acquire InstaDeep to Strengthen Pioneering Position in the Field of AI-powered Drug Discovery, Design and Development". Mainz & London....
• [8] Envisagenics, Inc.. (11/29/22). "Press Release: Envisagenics Announces Research Collaboration with Bristol Myers Squibb". New York, NY....
• [9] Turbine Simulated Cell Technologies Ltd.. (11/22/22). "Press Release: Turbine Raises €20 Million in Series A Financing to Advance Programs & Partnerships Towards the Clinic with World’s First Cancer Cell Simulation Platform". London & Budapest....
• [10] Envisagenics, Inc.. (8/2/22). "Press Release: Envisagenics is Awarded Another SBIR Grant From the National Cancer Institute to Commercialize its AI/ML Platform for Immunotherapy Development". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.